Ratnakar Securities Pvt. Ltd.

MANKIND PHARMA LTD.

NSE : MANKINDBSE : 543904ISIN CODE : INE634S01028Industry : Pharmaceuticals & DrugsHouse : Private

BSE2386.858.75 (+0.37 %)

PREV CLOSE ( ) 2378.10

OPEN PRICE ( ) 2389.95

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 9700

TODAY'S LOW / HIGH ( )2378.85 2437.70

52 WK LOW / HIGH ( )1910.1 3050

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 03-07 1991

Management Info

Ramesh Juneja - Chairman Rajeev Juneja - Managing Director

Registered Office

Address 208,Okhla Industrial Estate,Phase - 111,
New Delhi,
Delhi-110020

Phone 011-46846700

Email contact@mankindpharma.com

Website www.mankindpharma.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

10Jun Mankind Pharma informs about allotment
Mankind Pharma has informed that the Nomination and Remuneration Committ..

05Jun Mankind Pharma gets ESG score of 38.98
ISS ESG has voluntarily issued an Environmental, Social and Governance (..

05Jun Mankind Pharma gains on the BSE
Mankind Pharma is currently trading at Rs. 2357.25, up by 10.55 points o..

22May Mankind Pharma gets nod to incorporate
Mankind Pharma has received approval for incorporation of wholly owned s..

22May Mankind Pharma reports 11% fall in Q4
Mankind Pharma has reported results for fourth quarter (Q4) and year end..

Financials

in Millions

	QTR Mar 25	ANNUAL 25
Net Profit	3824.6	19454.8
Gross Profit	4287.5	23059.9
Operating Profit	6962.4	30557.6
Net Sales	21265.9	94978

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Vimta Labs (BSE) 1006.20 (3.26%)	M.Cap ( in Cr)2239.08
Supriya Lifescience (BSE) 699.90 (2.92%)	M.Cap ( in Cr)5632.99
Jenburkt Pharma (BSE) 1281.95 (1.22%)	M.Cap ( in Cr)565.76
Aayush Wellness (BSE) 160.20 (1.97%)	M.Cap ( in Cr)779.72
Parnax Lab (BSE) 107.45 (1.99%)	M.Cap ( in Cr)123.41

Shareholding Pattern

	PROMOTERS	72.7%
	MUTUAL FUNDS/UTI	7.67%
	NON-INSTITUTION	2.93%
	FI/BANKS/INSURANCE	2.23%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Tata Nifty MidSmall...	4.97
Motilal Oswal Nifty...	4.96
PGIM India Healthca...	4.90
Invesco India Focus...	3.88
SBI Healthcare Opp ...	3.76
Mirae Asset BSE Sel...	3.75

attention investors
kyc
ipo
ibt trading
KYC & KRA Status Awareness

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

MANKIND PHARMA LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES